These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29948972)

  • 1. Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma.
    Deng LL; Deng HB; Lu CL; Gao G; Wang F; Yang Y
    Clin Transl Oncol; 2019 Feb; 21(2):197-205. PubMed ID: 29948972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.
    Deng LL; Deng HB; Lu CL; Guo Y; Wang D; Yan CH; Lv X; Shao YX
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2097-105. PubMed ID: 24994038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
    El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S
    Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
    Jiang H; Wang H; Wang S; Pei Z; Fu Z; Fang C; Wang J; Lu Q; Wang E; Li J
    Mol Med Rep; 2015 May; 11(5):3523-32. PubMed ID: 25573098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer.
    Cao Y; Zhang G; Wang P; Zhou J; Gan W; Song Y; Huang L; Zhang Y; Luo G; Gong J; Zhang L
    BMC Gastroenterol; 2017 Jan; 17(1):2. PubMed ID: 28056823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer.
    Han Y; Wang XB; Xiao N; Liu ZD
    Asian Pac J Cancer Prev; 2013; 14(5):2987-90. PubMed ID: 23803067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
    Quéré G; Descourt R; Robinet G; Autret S; Raguenes O; Fercot B; Alemany P; Uguen A; Férec C; Quintin-Roué I; Le Gac G
    BMC Cancer; 2016 Mar; 16():210. PubMed ID: 26968843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer.
    Han Y; Yu DP; Zhou SJ; Song XY; Li YS; Xiao N; Liu ZD; Sun XJ; Zhao QY; Liu SK
    Genet Mol Res; 2014 Oct; 13(4):8913-24. PubMed ID: 25366782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiles of ERCC1, TYMS, RRM1, TUBB3 and EGFR in tumor tissue from non-small cell lung cancer patients.
    Yu D; Li J; Han Y; Liu S; Xiao N; Li Y; Sun X; Liu Z
    Chin Med J (Engl); 2014; 127(8):1464-8. PubMed ID: 24762590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma.
    Dormieux A; Mezquita L; Cournede PH; Remon J; Tazdait M; Lacroix L; Rouleau E; Adam J; Bluthgen MV; Facchinetti F; Tselikas L; Aboubakar F; Naltet C; Lavaud P; Gazzah A; Le Pechoux C; Lassau N; Balleyguier C; Planchard D; Besse B; Caramella C
    Eur Radiol; 2020 Sep; 30(9):5021-5028. PubMed ID: 32323012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer: Association with clinicopathological characteristics.
    Li J; Sun P; Huang T; He S; Li L; Xue G
    Medicine (Baltimore); 2021 Apr; 100(14):e25344. PubMed ID: 33832110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathological and molecular profiling of lung adenocarcinoma skin metastases reveals specific features.
    Forest F; Laville D; Habougit C; Da Cruz V; Casteillo F; Yvorel V; Bard-Sorel S; Godard W; Picot T; Tiffet O; Perrot JL; Péoc'h M
    Histopathology; 2021 Dec; 79(6):1051-1060. PubMed ID: 34313338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
    Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
    Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing.
    Li D; Huang Y; Cai L; Wu M; Bao H; Xu Y; Wei Y; Wu S; Wu X; Shao Y; Zhao W; Lv G; Huang S; Zhang T; Shi Y
    Neoplasia; 2021 Dec; 23(12):1204-1212. PubMed ID: 34735995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
    Gupta R; Amanam I; Rahmanuddin S; Mambetsariev I; Wang Y; Huang C; Reckamp K; Vora L; Salgia R
    Am J Clin Oncol; 2019 Apr; 42(4):337-344. PubMed ID: 30741758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.